Over the last decades, the technology of monoclonal antibodies which target the HER2 receptor developed rapidly and corresponding antibody–drug conjugates (ADCs) have been successfully explored for HER2-targeted cancer therapy by using antibodies as vehicles to deliver cytotoxic agents into tumor cells efficiently and selectively [3–6]. The gene discussed is ERBB2; the disease is neoplasm.